U.S., Oct. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07884942) titled 'Antimicrobial Resistance and Genomic Profiling of Bacterial Isolates' on Oct. 13.
Brief Summary: Sepsis and bloodstream infection (BSI) are among the most serious complications in patients with cancer, in whom disease- and treatment-related immunosuppression markedly increases susceptibility to infection. Sepsis accounts for approximately 15% of ICU admissions in this population, and short-term mortality is consistently higher than in patients without cancer (Bianchi et al., 2024).
In haematological malignancy, sepsis affects roughly 12-27% of patients within a year of diagnosis, and although in-hospital mortality has fallen over t...